Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
idiopathic pulmonary fibrosis
Biotech
Eli Lilly to pay Mediar $99M for pulmonary fibrosis prospect
Eli Lilly is making a play for the IPF market, offering Mediar $99 million in upfront and near-term payments for an asset that is entering phase 2.
Nick Paul Taylor
Jan 10, 2025 8:35am
Tvardi to go public via merger with cash-strapped Cara
Dec 18, 2024 10:37am
PureTech's lung fibrosis drug slows decline in phase 2 trial
Dec 16, 2024 7:00am
After phase 2 data, Insilico plots pivotal lung disease trial
Nov 12, 2024 1:34pm
The Column Group biotech taps Surrozen to target lung fibrosis
Nov 4, 2024 11:14am
Amgen disappears lung disease program after phase 2 fail
Oct 30, 2024 5:59pm
